This study is being done to test the safety and effectiveness of combining ZN-c3 and
Gemcitabine in participants with pancreatic cancer.
The names of the study drugs involved in this study are:
- ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase)
- Gemcitabine (a nucleoside metabolic inhibitor)
Phase:
Phase 2
Details
Lead Sponsor:
Brandon Huffman
Collaborators:
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Lustgarten Foundation Stand Up To Cancer